Resolved: Fistulas Are Preferred to Grafts as Initial Vascular Access for Dialysis : Journal of the American Society of Nephrology

Journal Logo



Fistulas Are Preferred to Grafts as Initial Vascular Access for Dialysis

Besarab, Anatole

Author Information
Journal of the American Society of Nephrology 19(9):p 1629-1633, September 2008. | DOI: 10.1681/ASN.2008020172
  • Free



Life-sustaining hemodialysis requires durable vascular access to the circulatory system.1 The ideal permanent vascular access must provide longevity of use with minimal complication rate and supply high enough blood flow to deliver the prescribed dialysis dosage. The native arteriovenous fistula is considered the best access to initiate patients onto hemodialysis because of its longer survival and lower complication rates as compared with other forms of vascular access, such as the synthetic graft. Large studies show a graded mortality risk from both cardiovascular and infectious diseases depending on access type, with the highest risk associated with catheters, followed by grafts, and then native fistulas.2 According to one analysis, the cost of vascular access care was more than five-fold lower in those who began treatment with a functioning native fistula compared with those who were treated with a graft or permanent catheter.3

The National Kidney Foundation published the Dialysis Outcome Quality Initiative (KDOQI) guidelines and opinion-based recommendations to improve vascular access outcomes.1 This document advocates greater use of fistulas, promotes elbow-level fistulas ahead of any graft in any anatomic location, encourages preoperative venous mapping and arterial evaluations, and vigorously endorses predialysis construction of vascular access before the need for initiation of dialysis. It also identified barriers to fistula placement in the preceding decade. These include preference by surgeon,4 local policies, degrees of access to tertiary care, reimbursement practices, and other financial issues penalizing fistula construction. Cardiovascular diseases, late referral, and use of catheters consistently predict shorter fistula survival, even accounting for concomitant comorbidities and other prognostic factors.5 Other factors that I believe have an impact on fistula use include older age of patients entering dialysis programs, disproportionate presence of diabetes with its vasculopathy, and presence of multiple comorbidities as a result of more “liberal” access to dialysis. Older age, diabetes, and cardiovascular diseases are associated with poor arterial and vein quality, making the construction of distal fistulas more challenging. Indeed, the choice of the fistula is strongly related to younger age, male gender, nondiabetic status, lower body mass index, no history of angina, and absence of peripheral vascular disease.6,7

To modify the observed suboptimal use of fistulas among incident patients and the continued use of synthetic graft for initial vascular access, the National Vascular Access Improvement Initiative was formulated. This evolved into the “Fistula First Breakthrough Initiative,” commonly known as Fistula First. The purpose of the initiative is to increase the likelihood that every suitable patient receives the most optimal form of vascular access (fistulas if possible) for that patient. Note the initiative does not exclude grafts or catheters. The initiative proved so successful that the goal for fistula use was revised to 66% of all hemodialysis patients by the year 2009. Whether the fistula prevalence rate can reach this goal by 2009 as desired by Centers for Medicare and Medicaid Services8 is uncertain.

My own experience with the Fistula First initiative suggests that multidisciplinary management is essential in increasing the likelihood of success and maintaining the fistulas as the preferred initial access for dialysis by avoiding construction of marginal nonmaturing or poorly functioning fistulas. Indeed, a number of US9,10 and Canadian11 programs have successfully increased the prevalence of native fistulas by implementing multiprofessional interdisciplinary programs. During a 2-yr period (2000–2001) with such a multidisciplinary team in place, vascular access tracking database, an aggressive interventional program to foster maturation, and a surveillance program to prevent access thrombosis, I was able to increase the prevalence of fistulas from 45 to 80% in our dialysis program in West Virginia (unpublished observations). By contrast, without these tools, I have struggled to keep up with the national trend for the past 6 yr.

Multiple past observations indicate the number of access procedures needed to maintain long-term patency is much lower for fistulas than for grafts, usually 2.5- to 7.0-fold lower.6,12 Some argue that this difference results from patient selection biases; that is, patients with best anatomy get fistula placement. Others argue the superior patency and lower intervention rate data are old1315 and no longer apply to patients currently initiating hemodialysis16,17; however, some recent studies continue to show overall lower procedure rates for fistulas than grafts.18

A key factor may be the initial failure rate of fistulas compared with grafts, because a higher initial failure rate with fistulas than with grafts automatically leads to prolonged catheter dependence for patients who must initiate dialysis before a permanent access is ready for use. Primary failure of fistulas (as a result of thrombosis or failure of maturation into a functional access) used to range from 10 to 20%6,13 but more recently is reported two to four times higher, in the 40 to 45% range.6,19,20 In fact, a recent prospective, 11-center European study reported an unexpectedly high primary failure rate of 40%.21 In this study, patency rates (access survival from creation) and potential risk factors that affect functional patency (survival from first dialysis use) were examined. Eighty-six percent of mature fistulas were still functional at 18 mo.21 Functional patency was adversely affected by diabetes or absence of surveillance, producing variation in secondary failure rates per hospital from 0 to 39%. Overall secondary patency was still good at 75, 70, and 67% at 6, 12, and 18 mo, respectively,21 and still higher than those reported for grafts.9,12,15,16

Thus, primary failure has an impact on the overall survival probability of the access. Unfortunately, the latter is frequent, occurring in up to 65% of incident patients17 despite the recommendations of KDOQI for predialysis management and access planning.1 One-year primary (intervention-free or unassisted) and secondary (assisted) survival probabilities of fistulas are greater than those of grafts after exclusion of early events but not when early events are included in the analyses.18,22 Avoidance of primary fistula failure, as a result of early failure or lack of maturation, is therefore the key area for vascular access outcomes. The main challenge for the nephrologist and surgeon is to minimize risk for primary failure while attempting to provide most patients with a native fistula. The longer period of catheter dependence in patients who are already on dialysis is associated with lower delivered dosages of dialysis and with higher infection risk.10 For some, the three-fold or more increase in catheter duration with its attendant risks for underdialysis and catheter-related bacteremia might obviate the other advantages of fistulas over grafts.17 The optimal time to do so is when the patient is incident to or is in fact predialysis.

Many elements must be in place if we are to succeed in increasing fistula prevalence without seeing the increase in catheter use that has accompanied fistulas, although there is no proof that increases in fistula placement and catheter use are in any way causally related. In my opinion, it is apathy and the underestimation of the opportunities to succeed even in “difficult” patients that produces an attitude of easy surrender and is responsible for the increasing use of catheters. I do not subscribe to therapeutic nihilism by adopting the position that a fistula in many of our elderly or morbidly obese patients is not feasible because vascular anatomy is unsuitable or veins have been ruined/exhausted by previous hospitalizations.

Autologous fistulas also remain underused among such patients because of late referral to nephrologists. Other specialists often see older patients for multiple comorbid conditions, who may engender hesitation or even reluctance to consider additional care plans. Indeed, as stated previously, the choice of the fistula implies a considerable initial effort in terms of care planning and access assistance, because in the short run, early failure or lack of maturation might be problematic.14 Although it has been reported that patients referred late to the nephrologist are likely to use catheters not only at initiation of dialysis but also in the subsequent months and are less likely to receive a fistula as permanent access, there is simply no explanation for the explicit preference for grafts over fistulas by some practices.4,14

Existence of multiple associations between clinical characteristics, suboptimal care before/around dialysis initiation, and type of vascular access in use raises the issue of indication bias that must be taken into account when interpreting the results of patient survival data and access type. Unmeasured or immeasurable factors (e.g., disease severity; vessel availability and degree of arterial sclerosis; other, unknown factors) mask residual confounding and predispose patients to both use of suboptimal vascular access and death.

Thus, a major issue is how to predict who is at risk for early fistula access failure from early thrombosis or failure to mature, because for these patients, the probability of failure might be so high that pursuing a fistulas is not justified; a “patient first, not fistula first, but avoid a catheter if at all possible” approach might be the best. Unfortunately, no easily accessible, valid, and reliable diagnostic test is available to provide clinicians with meaningful prognostic information that identifies risk for early thrombosis or early maturation failure. Quality (calcification)/diameter of the vessels, presence of cardiovascular diseases, normal or low BP, older age, and race all predict primary failure.5,19,20,22 Indeed, primary failure occurs with similar frequency in centers where preoperative vascular mapping is routinely used to guide the choice of access type and location22 as well as in programs where routine mapping is not in place.5

The best tool we have is a scoring system developed by Lok et al.20 to differentiate between early surgical failure, as a result of thrombosis or technical complications, and failure to mature. Failure to mature was defined is this study as a fistula that was used for hemodialysis and was unable to provide the prescribed dialysis dosage through two-needle cannulation consistently (in effect, two-needle cannulation for two thirds or more of all dialysis runs) for 1 mo within 6 mo of its creation, despite interventions to facilitate maturation. They found four risk categories for failure to mature (low, moderate, high, and very high) and validated a simple and easily reproducible preoperative, clinical prediction rule to determine fistulas that are likely to fail maturation. These categories predicted a risk for failure to mature estimated at 24, 34, 50, and 69% on the basis of age, coronary artery disease, peripheral vascular disease, and race.20

Despite such efforts, it is unclear whether the best option for the patient at high risk for primary failure is to receive an arteriovenous graft or to receive a fistula anyway once optimal strategies to treat modifiable risk factors for early thrombosis and lack of maturation (hypovolemia and cardiac diseases) have been addressed. Indeed, a substantial proportion of patients with marginal fistulas may still undergo successful salvage procedures or receive successful placement of a new fistula after a former fistula has failed.23 Alternatively, some advocate the placement of a forearm loop graft when the artery or veins in the forearm are unsuitable for primary fistula construction to mature the vein in the upper arm followed by a strategy of conversion to an elbow-level fistula rather than attempts to salvage a graft with repeated interventions. For some patients, I have advocated the latter.



Published online ahead of print. Publication date available at


1. NKF-K/DOQI clinical practice guidelines for vascular access: Update 2006. Am J Kidney Dis 48 [Suppl 1]: S176 –S276, 2006
2. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J: Type of vascular access and survival among incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol 16 : 1449 –1455, 2005
3. Lee H, Manns B, Taub K, Ghali WA, Deab S, Johnson D, Donaldson C: Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 40 : 611 –622, 2002
4. O'Hare AM, Dudley RA, Hynes DM, Mcculloch CE, Navarro D, Colin P, Stroupe K, Rapp J, Johansen KL: Impact of surgeon and surgical center characteristics on choice of permanent vascular access. Kidney Int 64 : 681 –689, 2003
5. Ravani P, Barrett B, Mandolfo S, Brunori G, Camcarini G, Imbasciati E, Malberti F: Factors associated with unsuccessful utilization and early failure of the arterio-venous fistula for hemodialysis. J Nephrol 18 : 188 –196, 2005
6. Allon M, Robbin ML: Increasing arteriovenous fistulas in hemodialysis patients: Problems and solutions. Kidney Int 62 : 1109 –1124, 2002
7. Lee T, Barker J, Allon M: Associations with predialysis vascular access management. Am J Kidney Dis 43 : 1008 –1013, 2004
8. End Stage Renal Disease (ESRD) Quality Initiative: Fistula First Breakthrough. Available at
9. Perera GB, Mueller MP, Kubaska SM, Wilson SE, Lawrence PF, Fujitani RM: Superiority of autogenous arteriovenous hemodialysis access: Maintenance of function with fewer secondary interventions. Ann Vasc Surg 18 : 66 –73, 2004
10. Glazer S, Diesto J, Crooks P, Yeoh H, Pascual N, Selevan D, Derose S, Farooq M: Going beyond the kidney disease outcomes quality initiative: Hemodialysis access experience at Kaiser Permanente Southern California. Ann Vasc Surg 20 : 75 –82, 2006
11. Lok C, Oliver M: Overcoming barriers to arteriovenous fistula creation and use. Semin Dial 16 : 189 –196, 2003
12. Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO: Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg 34 : 694 –700, 2001
13. Kinnaert P, Vereerstraeten P, Toussaint C, Van Geertruyden J: Nine years’ experience with internal arteriovenous fistulas for haemodialysis: A study of some factors influencing the results. Br J Surg 64 : 242 –246, 1977
14. Young EW, Dykstra DM, Goodkin DA, Mapes DL, Wolfe RA, Held PJ: Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 61 : 2266 –2271, 2002
15. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61 : 305 –316, 2002
16. Huber TS, Carter JW, Carter RL, Seeger JM: Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: A systematic review. J Vasc Surg 38 : 1005 –1011, 2003
17. Lee T, Barker J, Allon M: Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula. J Am Soc Nephrol 18 : 1936 –1941, 2007
18. Oliver MJ, McCann RL, Indridason OS, Butterly DW, Schwab SJ: Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int 60 : 1532 –1539, 2001
19. Feldman HI, Joffe M, Rosas SE, Burns JE, Knauss J, Brayman K: Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis 42 : 1000 –1012, 2003
20. Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D: Risk Equation Determining Unsuccessful Cannulation Events and Failure to Maturation in Arteriovenous Fistulas (REDUCE FTM I). J Am Soc Nephrol 17 : 3204 –3212, 2006
21. Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, Blankestijn PJ, on behalf of the CIMINO study group: Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative. Clin J Am Soc Nephrol February 6, 2008 [epub ahead of print]
22. Allon M, Lockhart ME, Lilly RZ, Gallichio MH, Young CJ, Barker J, Deierhoi MH, Robbin ML: Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 60 : 2013 –2020, 2001
23. Ravani P, Marcelli D, Malberti F: Vascular access surgery managed by renal physicians: The choice of native arteriovenous fistulas for hemodialysis. Am J Kidney Dis 40 : 1264 –1276, 2002
Copyright © 2008 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.